Foresite Capital is a multi-stage healthcare and life sciences investment firm that uses a data science-driven approach to invest in companies leveraging biology and big data to transform healthcare. Founded in 2011 and headquartered in Larkspur, California, the firm manages approximately $3.5 billion in assets.
48% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $118.7M (across 180 rounds with reported amounts).
Portfolio
131
Fund Size
$900M
Top Stage
Series B
Last 12 Mo
9
Team
Dorothy Margolskee, MD
Managing Director
Michael Rome, PhD
Managing Director
Richard Lau, CFA
Managing Director
Stephen C. Peterson, CFA
Managing Director
Hyung Chun, MD
Partner
Jorge Reis-Filho, MD, PhD, FRCPath
Venture Partner
Liang Chang, PhD
Venture Partner
Mike Lai, MD
Venture Partner
Travis Young, PhD
Venture Partner
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Thyme | Series E | $125M | Sep 2026 |
 Khartis Therapeutics | Series B | $50M | Aug 2026 |
 Pinnacle Medicines | Series B | $89M | Mar 2026 |
| Pinnacle Medicines | Series B | $89M | Mar 2026 |
 Slate Medicines | Series A | $130M | Feb 2026 |
 Midi | Series D | $100M | Feb 2026 |
 Third Arc Bio | Series A | $52M | Feb 2026 |
 OnKure Therapeutics | Series C | $150M | Jan 2026 |
 Thyme Care | Series D | $97M | Sep 2025 |
| Thyme | Series D | $97M | Sep 2025 |
 Avenzotx | Series B | $60M | Sep 2025 |
 Latigo Biotherapeutics | Series B | $150M | Mar 2025 |
 Eikon Therapeutics, Inc. | Series D | $350.7M | Feb 2025 |
 Abcuro, Inc. | Series C | $200M | Feb 2025 |
 Avenzo Therapeutics | Series B | $60M | Jan 2025 |
 Korsana Biosciences | Series A | $150M | Jan 2025 |
 Kriya Therapeutics | Series D | $320M | Jan 2025 |
 RAPT Therapeutics | Series D | $150M | Dec 2024 |
 Pleno | Series A | $40M | Dec 2024 |
| Pleno | Series B | $25M | Dec 2024 |
 Sollis Health | Series B | $33M | Dec 2024 |
| SSollis | Series B | $33M | Dec 2024 |
| Avenzo Therapeutics | Unknown | $386M | Nov 2024 |
| Avenzotx | Unknown | $386M | Nov 2024 |
| VVerve Therapeutics | Series C | $213M | Oct 2024 |
Top Co-Investors
Last updated: 7 October 2026